US Patent

US11959486 — Stable liquid formulation of AMG 416 (etelcalcetide)

Method of Use · Assigned to Amgen Inc · Expires 2034-06-27 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent provides a stable liquid formulation of the peptide agonist etelcalcetide and methods for preparing and using it.

USPTO Abstract

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

Drugs covered by this patent

Parsabiv (ETELCALCETIDE) · Kai Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2014`	—	Parsabiv
`U-2014`	—	Parsabiv
`U-2014`	—	Parsabiv

Patent Metadata

Patent number: US11959486
Jurisdiction: US
Classification: Method of Use
Expires: 2034-06-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Amgen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.